The generative artificial intelligence usage in pharma and healthcare can potentially go on to address the long-standing issues when it comes to high costs as well as poor experiences within the sector, as per a report by GlobalData.
It is well worth noting that generative AI is all set to bring monumental changes to the healthcare sector and also enable a major transition across the value chain, opines the practise head for Disruptive Tech, Kiran Raj, at GlobalData.
The technology can go on to help the physicians provide more effective care, and that too at a lower cost, with streamlined and personalised care as well as guided diagnosis. GlobalData, in its latest report pertaining to Innovation Radar, mentioned that AI could go on to synthesise critical information about patients, which can include their medical history, lifestyle, or family history too.
When it comes to the drug discovery scene, generative AI can aid in helping to generate new drug candidates that are purely based on the criteria and constraints that are supplied by the researchers.
The technology can also go on to predict the efficacy and safety of the new drug candidates and potentially customise the drug therapy for better patient outcomes.
Companies around the world are already on the move when it comes to discovering the next biggest innovation in the industry, as per the report. As per GlobalData, health startups such as Absci, Huma.AI, and Insilico Medicine are all currently creating generative models that can aid in fast-track development, while technology giants like Google and NVIDIA can go on to help with the required infrastructure.
The firm’s associate project manager, Saurabh Daga, who is involved in Disruptive tech, said that the genAI gamut is not without any risks, especially when it comes to regulated sectors such as pharma and healthcare, where there is immense potential for advancements as well as benefits.
So as to entirely leverage the potential of tech breakthroughs, Daga went on to stress the fact that there is indeed a need for companies to partner with organisations that have a sector perspective as well as tech expertise, which involves responsible AI.
